Welcome to our dedicated page for Invivyd SEC filings (Ticker: IVVD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Invivyd, Inc. (Nasdaq: IVVD) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Invivyd is a Delaware-incorporated biopharmaceutical company whose common stock is listed on The Nasdaq Stock Market LLC under the symbol IVVD, as noted in multiple Form 8-K reports.
Through this page, readers can review Invivyd’s current and historical Form 8-K filings, which describe material events such as public offerings of common stock and pre-funded warrants, entry into underwriting agreements, clinical and regulatory milestones for its monoclonal antibody programs, and corporate governance changes. Examples include 8-Ks detailing underwritten offerings to fund commercial preparedness for VYD2311, research and development for RSV and measles programs, and formation of the SPEAR Study Group to study monoclonal antibody therapy for Long COVID and COVID-19 post-vaccination syndrome.
Invivyd’s filings also reference press releases on topics such as U.S. IND clearance and FDA alignment on the pivotal clinical program for VYD2311, Fast Track designation for VYD2311, selection of the RSV antibody candidate VBY329, and financial results for recent quarters. Other 8-Ks note Nasdaq correspondence regarding the company’s compliance with minimum bid price requirements and confirm that the matter was resolved after the company regained compliance.
On Stock Titan, Invivyd filings are updated as they appear on EDGAR, and AI-powered tools summarize key points from each document. Users can quickly identify why a filing was made, what agreements or clinical developments it describes, and how it relates to Invivyd’s antibody pipeline, EUA-authorized PEMGARDA product, and capital-raising activities. This helps investors and researchers navigate lengthy regulatory documents and focus on the disclosures most relevant to IVVD’s business and stock.
A shareholder of Invivyd (symbol IVVD) has filed a notice of proposed sale of 39,600 shares of common stock, with an aggregate market value of
The seller acquired 99,000 common shares on
Invivyd Inc. filed a Form 144 notice for a planned resale of 66,000 shares of its common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC on the Nasdaq, with an aggregate market value of $102,960.00 based on the filing.
The securities relate to common stock acquired on 02/15/2026 upon vesting of restricted stock units granted under the company’s 2021 Equity Incentive Plan as equity compensation. The company reported 281,987,033 common shares outstanding in the same class at the time referenced in the notice.
Invivyd, Inc.RA Capital Management, L.P., its RA Capital Healthcare Fund, and managers Peter Kolchinsky and Rajeev Shah. They report beneficial ownership of 28,857,208 shares of Invivyd common stock as of December 31, 2025, equal to 9.99% of the company.
The fund directly holds 17,119,096 common shares plus pre‑funded warrants exercisable for up to 21,342,442 additional shares, but a “Beneficial Ownership Blocker” in the warrants caps their ownership at 9.99%. The percentage is calculated using 233,122,834 shares outstanding as of October 30, 2025, 44,000,000 shares sold in November 2025, and 11,738,112 shares issuable upon warrant exercise. The reporting parties state the holdings are not for the purpose of changing or influencing control and include standard disclaimers about beneficial ownership status under Section 13(d).
Invivyd, Inc. received an updated ownership report showing that investment firms associated with Point72 and Steven A. Cohen beneficially own 16,653,036 shares of its common stock, representing 6.0% of the company as of December 31, 2025.
The shares are held by Point72 Associates, LLC, with investment and voting power managed by Point72 Asset Management, L.P., while Point72 Capital Advisors, Inc. is its general partner and Mr. Cohen controls both entities. The reported percentage is based on 277,064,852 shares outstanding as of the completion of Invivyd’s underwritten public offering that closed on November 17, 2025. The reporting parties state the securities were not acquired to change or influence control of Invivyd.
Invivyd, Inc. received an updated ownership report from Biotechnology Value Fund and related entities, which together may be deemed to beneficially own 25,525,000 shares of Invivyd common stock, or approximately 9.0% of the company, as of December 31, 2025. This includes holdings of Pre-Funded Warrants exercisable for 6,000,000 shares at an exercise price of $0.0001 per share, subject to a 9.99% ownership blocker that limits exercises above that threshold. The group states the securities are not held for the purpose of changing or influencing control of Invivyd, outside of activities solely in connection with a nomination under relevant proxy rules.
Maverick Capital and related entities report a passive stake in Invivyd, Inc. (IVVD). As of December 31, 2025, Maverick Capital, Ltd., Maverick Capital Management, LLC, and Lee S. Ainslie III collectively report beneficial ownership of 18,970,913 shares of Invivyd common stock, representing 6.7% of the outstanding shares, based on 281,987,033 shares reported by the company. The shares are held in client accounts of Maverick-managed funds, and the filers certify that the holdings were not acquired to change or influence control of Invivyd.
Invivyd, Inc. (IVVD) received an amended Schedule 13G showing that a group of Soleus-affiliated investment entities and Guy Levy collectively report beneficial ownership below 5% of its common stock. The filing is based on an event dated December 31, 2025.
Soleus Private Equity Fund III, L.P. and related Soleus private equity entities each report beneficial ownership of 1,680,160 shares, representing 0.6% of Invivyd’s common stock. Separately, Soleus Capital Master Fund, L.P. and related Soleus capital entities each report 6,028,567 shares, or 2.2% of the class.
Soleus Capital Management, L.P., Soleus GP, LLC and Guy Levy each report beneficial ownership of 7,708,727 shares, equal to 2.8% of Invivyd’s outstanding common stock, all with shared and no sole voting or dispositive power. The percentages are calculated using 277,064,852 Invivyd shares outstanding immediately after an underwritten offering described in a prospectus supplement. The reporting persons state the securities were not acquired and are not held for the purpose of changing or influencing control of Invivyd.
Invivyd, Inc.’s Chief Financial Officer William E. Duke received a new stock option grant. On January 29, 2026, he was awarded options to purchase 625,000 shares of Invivyd common stock at an exercise price of $1.85 per share.
The options vest over three years, with 1/36th of the total vesting in substantially equal monthly installments starting one month after the grant date, contingent on his continuous service with the company.
Invivyd, Inc. reported that Chief Human Resources Officer Julie Green received a grant of stock options on January 29, 2026. The award covers 675,000 options to buy common stock at an exercise price of
The options vest over three years, with 1/36th of the grant vesting in substantially equal monthly installments starting one month after the grant date, contingent on her continued service. Following this award, she holds 675,000 stock options directly.
Invivyd, Inc. reported a new equity award to its Chief Commercial Officer, Timothy Edward Lee. On January 29, 2026, he received a stock option to purchase 675,000 shares of common stock at an exercise price of $1.85 per share.
The option vests over three years, with 1/36th of the shares vesting in substantially equal monthly installments starting one month after the grant date, subject to his continuous service at each vesting date. Following this grant, he beneficially owns 675,000 derivative securities directly.